How to Benchmark Digital Screening Against Traditional Exam Accuracy

The question insurance carriers keep circling back to is straightforward but hard to answer well: how does digital health screening accuracy actually stack up against a traditional paramedical exam? Benchmark digital screening against traditional exam accuracy is something underwriting teams talk about constantly, but the methodology behind a fair comparison is surprisingly underdeveloped. Most carriers rely on gut instinct or vendor claims. Neither is good enough when mortality assumptions are on the line.

"When we compared accelerated underwriting decisions made with digital evidence against full traditional underwriting on the same applicant pool, the mortality impact was measurably smaller than most actuaries expected." — RGA's 2024 Digital Underwriting Evidence study

Why benchmarking digital screening accuracy matters for underwriting

The insurance industry spent decades building confidence in paramedical exam data. Blood chemistry panels, urinalysis, blood pressure readings from calibrated sphygmomanometers — these formed the foundation of risk classification. When digital screening entered the picture, the natural response was skepticism. And honestly, some of that skepticism was warranted.

But the conversation has shifted. A 2024 Milliman analysis found that 36% of companies now use accelerated underwriting for term life policies, and that number keeps climbing. LIMRA's research on accelerated underwriting adoption shows satisfaction scores running significantly higher among applicants who go through digital processes. The question is no longer whether carriers will adopt digital screening. It is whether they can measure its accuracy rigorously enough to satisfy actuarial teams and reinsurers.

The challenge is that "accuracy" means different things depending on who you ask. An underwriter cares about whether digital data leads to the same risk classification as traditional methods. An actuary cares about whether mortality experience on digitally underwritten policies tracks expectations. A product manager cares about whether the screening catches enough to avoid anti-selection. Each perspective requires a different benchmarking approach.

Comparison of benchmarking methods

The following table breaks down the main approaches carriers use to benchmark digital screening against traditional exams, along with the strengths and blind spots of each.

Benchmarking method	What it measures	Data requirement	Time to results	Limitations
Parallel underwriting study	Decision concordance between digital and traditional paths on the same applicants	Dual-path submissions on a sample cohort	3-6 months	Expensive; requires running both processes simultaneously
Retrospective decision comparison	Whether digital evidence would have changed historical underwriting decisions	Access to historical case files and digital data sources	1-3 months	Hypothetical; digital data was not actually used in original decisions
Mortality experience tracking	Whether actual claims on digitally underwritten policies match pricing assumptions	3-5 years of in-force policy data	3-7 years	Long feedback loop; confounded by other underwriting changes
Vital sign concordance testing	How closely digital vitals readings match clinical-grade device measurements	Paired measurements from digital and reference devices	1-3 months	Measures input accuracy, not underwriting outcome accuracy
Predictive model validation	Whether digital data inputs improve mortality model discrimination	Large historical dataset with outcomes	6-12 months	Requires actuarial modeling infrastructure

No single method gives the full picture. Carriers running serious benchmarking programs typically combine at least two of these approaches.

Parallel underwriting: the gold standard that few actually run

The most rigorous benchmarking method is a parallel underwriting study. You take a cohort of applicants, run them through both the traditional paramedical exam process and the digital screening process, and compare the underwriting decisions side by side.

RGA published findings from exactly this type of study in their 2024 analysis of digital underwriting evidence. They compared full underwriting decisions against accelerated underwriting decisions enhanced with digital evidence on the same applicant populations. The mortality impact gap between the two paths was narrower than industry expectations, suggesting that digital evidence compensates for the absence of fluid testing more effectively than assumed.

What a parallel study actually involves

Running a parallel study means every applicant in the test cohort completes both processes. They do the paramedical exam with blood draw, urine collection, and physical measurements. They also complete the digital screening with smartphone-based biometric capture and electronic health record pulls. Neither result influences the other; both are evaluated independently by separate underwriting teams or decision engines.

The output is a concordance matrix showing how often the two paths arrive at the same risk classification. A well-designed study also tracks the direction of disagreement. Does digital screening tend to be more conservative (assigning higher risk classes) or more permissive? The answer matters enormously for pricing.

The reason few carriers run these studies is cost. Processing every applicant twice doubles the per-case expense during the study period. Most carriers settle for retrospective analysis instead.

Vital sign concordance: measuring the inputs

Before you can trust digital underwriting decisions, you need to trust the underlying measurements. This is where vital sign concordance testing comes in.

A 2025 study published in the Annals of Emergency Medicine by Lam et al. evaluated remote photoplethysmography (rPPG) measurements against clinical-grade reference devices in a Hong Kong emergency department setting. The study found strong correlation between rPPG-derived heart rate and pulse oximetry reference measurements, with mean absolute error rates low enough for screening applications. This is particularly relevant because emergency department patients represent a stressed, diverse population — not the controlled-environment subjects that inflate performance numbers in lab studies.

A separate clinical validation study published in PMC in 2025 evaluated rPPG-enabled contactless pulse rate monitoring specifically in cardiovascular disease patients. The researchers found that accuracy held up in a population with known cardiac conditions, which is exactly the cohort where screening tools face the toughest test.

What concordance testing looks like in practice

A carrier running vital sign concordance testing collects paired measurements. The applicant sits for a blood pressure reading from a calibrated sphygmomanometer while simultaneously completing a digital biometric capture. Heart rate from a pulse oximeter gets compared against rPPG-derived heart rate. The statistical comparison typically uses Bland-Altman analysis to assess agreement and identify systematic bias.

The key metrics to track in concordance testing:

• Mean absolute error (MAE) between digital and reference measurements
• Limits of agreement from Bland-Altman plots
• Correlation coefficient (though this can be misleading on its own)
• Percentage of readings falling within clinically acceptable thresholds
• Performance stratification by skin tone, age, and ambient lighting conditions

That last point deserves emphasis. Early rPPG research showed performance variation across skin tones and lighting conditions. More recent deep learning approaches documented in a comprehensive review published in BioMedical Engineering OnLine (2025) show that algorithmic improvements have substantially narrowed these gaps, though carriers should still test across their specific applicant demographics.

Retrospective decision comparison: practical but imperfect

Most carriers that benchmark digital screening use retrospective analysis because it does not require the expense of running dual processes. The approach works like this: take a set of historically underwritten cases where full traditional evidence was collected, then retroactively evaluate what the underwriting decision would have been using only digital evidence.

Building the comparison dataset

The dataset needs to include cases across the full spectrum of risk classifications, not just standard risk applicants. If you only test cases that were already classified as preferred best, you are not really testing anything. The interesting cases are the ones on the boundary between standard and substandard, where the marginal evidence from a fluid panel might change the decision.

EasySend's research on digital data intake in underwriting found that digital processes improve consistency by removing the subjective interpretation inherent in manual data entry and review. This is an underappreciated dimension of accuracy. Two underwriters reviewing the same traditional exam paperwork might arrive at different conclusions. A digital decision engine produces the same output every time for the same inputs.

Mortality experience: the ultimate benchmark that takes years

The definitive answer to whether digital screening is accurate enough comes from mortality experience analysis. If policies underwritten with digital screening produce actual-to-expected mortality ratios in line with pricing assumptions, the screening works. If claims come in higher than expected, something was missed.

LIMRA and the Society of Actuaries maintain industry experience studies that track mortality outcomes across product lines and underwriting methods. Their Experience Studies Pro program provides carriers with benchmarking data against industry averages. As digital underwriting volume grows, these studies will increasingly segment results by underwriting method, giving the industry its first real mortality-based accuracy comparison.

The problem is time. Meaningful mortality data requires at least three to five years of in-force exposure, and early mortality is a poor predictor of ultimate experience on term life policies. Carriers that launched accelerated underwriting programs in 2020-2021 are just now entering the window where early experience data becomes interpretable.

What early mortality data shows

RGA's analysis of digital underwriting evidence provided some of the first structured mortality impact estimates. Their research presented a range of mortality impacts for accelerated underwriting programs with and without digital evidence, and found that adding digital evidence sources (electronic health records, prescription histories, motor vehicle records, and biometric data) meaningfully narrowed the mortality gap compared to programs relying solely on simplified questionnaires.

The Milliman study referenced in LIMRA's research found that companies using sophisticated data mining in their accelerated programs reported tighter actual-to-expected ratios than those using simpler qualification criteria. The data is directional rather than definitive, but the direction is encouraging.

Building your benchmarking program

A carrier that wants to benchmark digital screening against traditional exam accuracy should approach it in phases rather than trying to answer every question at once.

Phase 1: input validation (months 1-3)

Start with vital sign concordance testing. Collect paired measurements on a sample of applicants and run the statistical comparisons. This establishes whether the raw biometric inputs from digital screening are accurate enough to feed into underwriting rules. If the inputs are unreliable, nothing downstream matters.

Phase 2: decision concordance (months 3-9)

Run a retrospective decision comparison on at least 500 historical cases spanning the full range of risk classifications. Measure concordance rates, identify systematic bias, and quantify the percentage of cases where the digital path produces a materially different risk classification.

Phase 3: prospective monitoring (ongoing)

Once digital screening is in production, implement ongoing monitoring of actual-to-expected mortality on digitally underwritten policies. Set up reporting that segments experience by underwriting path, face amount band, and issue age. Review quarterly with actuarial and reinsurance partners.

Current research and evidence

The research base supporting digital screening accuracy has expanded considerably since 2023. The Frontiers in Digital Health journal published a comprehensive review of remote photoplethysmography for health assessment in 2025, covering both conventional signal processing and deep learning approaches. The review found that deep learning methods show superior accuracy over conventional techniques in non-contact heart rate estimation, with performance improvements particularly pronounced in challenging conditions like motion and variable lighting.

Snorkel AI's 2026 research on building agentic insurance underwriting benchmarks introduced structured evaluation frameworks for AI-driven underwriting decisions. Their dataset measured accuracy across specific underwriting tasks, with deductible assessment reaching 78.4% accuracy and business classification at 77.2%. While these numbers reflect the broader underwriting decision process rather than biometric screening specifically, they establish methodology for how the industry can standardize accuracy measurement.

The CX Pilots 2026 benchmark report on digital customer experience in insurance found that 47% of all insurance policy purchases now occur through digital channels, up from 35% through traditional agent channels. This adoption curve is creating the volume of digitally screened policies needed for statistically credible mortality experience analysis.

The future of digital screening benchmarks

The benchmarking conversation is going to change shape over the next two to three years. As more carriers accumulate mortality experience on digitally underwritten policies, the industry will move from theoretical accuracy comparisons to empirical outcome data. That shift will be decisive.

Reinsurers are already building frameworks for evaluating digital underwriting programs. The next step is industry-standardized benchmarking protocols that allow carriers to compare their digital screening accuracy against peers using consistent methodology. LIMRA's experience studies infrastructure is well positioned to support this, though it will require participating carriers to segment their submissions by underwriting method.

The carriers that invest in rigorous benchmarking now will have a meaningful advantage. They will be able to demonstrate to reinsurers, regulators, and their own boards that digital screening meets or exceeds traditional exam accuracy for specific applicant segments. That evidence base is what unlocks broader adoption and higher face amount thresholds for accelerated programs.

Frequently asked questions

How accurate is digital health screening compared to a traditional paramedical exam?

The answer depends on what you are measuring. For vital sign inputs like heart rate, recent clinical studies show rPPG measurements achieving strong correlation with reference devices, with mean absolute error rates within clinically acceptable thresholds. For underwriting decision concordance, RGA's research found that accelerated programs enhanced with digital evidence produce mortality impacts closer to full underwriting than programs without digital evidence. The gap is real but narrower than most people assume.

What sample size do I need for a reliable benchmarking study?

For vital sign concordance testing, 100-200 paired measurements provides statistically meaningful Bland-Altman analysis. For decision concordance studies, aim for at least 500 cases spanning the full range of risk classifications, with oversampling of borderline cases. For mortality experience analysis, you need thousands of policies with several years of exposure before the data becomes interpretable.

Can digital screening fully replace the paramedical exam?

For many applicant segments, yes. Carriers are already issuing policies up to $1-3 million in face amount using accelerated underwriting without fluid testing. The appropriate threshold depends on your risk appetite, reinsurance arrangements, and the specific combination of digital evidence sources in your program. Benchmarking data helps you identify exactly where the accuracy crossover occurs for your book of business.

How do reinsurers evaluate digital screening accuracy?

Reinsurers typically want to see three things: vital sign concordance data showing input accuracy, decision concordance data showing underwriting consistency, and early mortality experience data showing outcome alignment. RGA, Swiss Re, and Munich Re have all published frameworks for evaluating digital underwriting programs, and most are willing to participate in benchmarking studies with ceding companies.

---

Carriers exploring how digital screening technology fits into their underwriting programs can find platform information and integration details at Circadify's insurance solutions page. For related reading on this site, see our analysis of phone camera vs wearable vitals for underwriting and our guide to digital vs in-person insurance screening.